|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:ABC_Biotech
|
|
gptkbp:awards
|
Best_Biotech_Company_2021
|
|
gptkbp:budget
|
2022 Annual Report
|
|
gptkbp:clinicalTrials
|
Phase 2 Trials
Phase 3 Trials
Phase 1 Trials
|
|
gptkbp:collaborations
|
gptkb:University_of_Science
|
|
gptkbp:competitors
|
gptkb:DEF_Biologics
gptkb:XYZ_Pharmaceuticals
gptkb:ABC_Biotech
|
|
gptkbp:employees
|
200
|
|
gptkbp:founded
|
2000
|
|
gptkbp:founder
|
Jane_Smith
|
|
gptkbp:headCoach
|
gptkb:Mr._James_Black
gptkb:Dr._Emily_White
gptkb:Ms._Sarah_Green
Mr._Mark_Silver
Mr._Robert_Gray
Ms._Anna_White
Ms._Linda_Blue
Ms._Rachel_Gold
|
|
gptkbp:headOfMarketing
|
gptkb:Mr._Tom_Brown
|
|
gptkbp:headquarters
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AIG Global Biotechnology
|
|
gptkbp:industry
|
Biotechnology
|
|
gptkbp:insuranceAccepted
|
Mr._Paul_Red
|
|
gptkbp:investmentFocus
|
gptkb:Venture_Capital_Firm_B
$100 million in R&D
Private Equity Firm C
Venture_Capital_Firm_A
|
|
gptkbp:keyPeople
|
gptkb:John_Doe
|
|
gptkbp:market
|
Global
|
|
gptkbp:mission
|
Innovate in biotechnology
|
|
gptkbp:partnerships
|
gptkb:XYZ_Pharmaceuticals
|
|
gptkbp:patentCitation
|
50+ patents
|
|
gptkbp:products
|
Vaccines
Gene Therapy
Monoclonal Antibodies
|
|
gptkbp:researchFocus
|
Immunology
Oncology
Neurology
|
|
gptkbp:revenue
|
$500 million
|
|
gptkbp:services
|
Biopharmaceuticals
|
|
gptkbp:socialResponsibility
|
Community outreach programs
Sustainability initiatives
Ethical research practices
|
|
gptkbp:subsidiary
|
AIG_Biopharma
|
|
gptkbp:trademark
|
AIG_Biotech
AIG_Gene_Therapy
AIG_Immuno
|
|
gptkbp:vision
|
Transform healthcare through biotechnology
|
|
gptkbp:website
|
www.aigbiotech.com
|